Syndeio Biosciences推出专注于修复和增强中枢神经系统疾病突触功能的精密神经疗法

• Clinical portfolio, informed by deep and novel synapse biology and pharmacology insights, aims to strengthen neural connections through event-driven pharmacology
   
• Lead candidate zelquistinel is currently enrolling a Phase 2 study in major depressive disorder, soon to be trialed in Alzheimer's disease, and will be featured in an oral presentation at the ASCP Annual Meeting this week
   
• Over $90 million raised to date from dedicated investor syndicate, including Catalio Capital Management, Innoviva, Tenmile, Luson Bioventures, Palo Santo, with strategic shareholders AbbVie and Lilly
   
• Stellar team of experienced neurotherapeutics entrepreneurs, including founders of Naurex (acq. by Allergan) and Karuna Therapeutics (acq. by BMS), as well as Nobel Laureate Thomas C. Südhof, Co-founder of Syndeio and Co-chair of the SAB

Syndeio Biosciences today announced its launch to pioneer precision neurotherapeutics focused on repairing and enhancing synaptic function in central nervous system (CNS) diseases. The company's clinical-stage pipeline and proprietary R&D platform are built on cutting-edge discoveries in synapse biology and translational biomarkers, with a mission to transform treatment for patients suffering from major depressive disorder (MDD), Alzheimer's disease, schizophrenia, and other synaptopathies.

Syndeio is building from over $90 million raised to date from a syndicate of leading life science investors, including Catalio Capital Management and Innoviva, and participation from Tenmile, Luson Bioventures, and Palo Santo, with AbbVie and Lilly as strategic shareholders.